Chilling. It isn’t often that a bit of news is a perfect fit to that one-word description, but the recent decision by a Los Angeles jury in the first case to be decided pitting Johnson & Johnson (J&J; New Brunswick, New Jersey) against what is a cast of thousands of litigants is nothing short of that. Oh sure, there’s the usual post-decision posturing by the company per appealing the $8.3 million-plus jury award, but c’mon folks, the implications of this case for the medical-products giant – and truly for all other companies trying to do business in the med-tech space...
Stentys (Princeton, New Jersey), a company commercializing in Europe a Self-Apposing Stent to treat acute myocardial infarction (AMI), unveiled one-year results of the APPOSITION III clinical trial in 1,000 patients post treatment of a severe heart attack at the American College of Cardiology's Scientific (ACC; Bethesda, Maryland) Session & Expo.